Mental Health Assessment and Prescribing by Alberta Pharmacists
Major Depressive Disorder | Generalized Anxiety Disorder | Pharmacist-Patient RelationsThis is a clinical trial evaluating the experimental intervention of enhanced pharmacist care by pharmacists with additional prescribing authorization (APA) in Alberta, for patients newly diagnosed with Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD).
null
Conditions de participation
-
Sexe:
ALL -
Âges admissibles:
18 and up
Critères de participation
Inclusion criteria:
* Adults (≥ 18 years of age) newly diagnosed with MDD and/or GAD, including:
* Patients starting on medications for the management of adults with MDD
* Patients starting on medications for the management of GAD
Exclusion Criteria:
* Pregnancy
* Non-Alberta residents
* Unwilling or unable to participate in regular follow-up visits
* Unwilling to participate/sign consent form
* ≥2 suicide attempts per year
* Severe, psychotic, and catatonic depression
* History of and/or current substance abuse, intoxication, addiction or withdrawal
* Patients diagnosed with comorbid anxiety disorders other than GAD, including: panic -disorder, agoraphobia, specific phobia, social anxiety disorder, obsessive-compulsive disorder, posttraumatic stress disorder
* Patients diagnosed with comorbid depressive disorder other than MDD, including: depressive disorder due to another medical condition (e.g. hypothyroidism, MS, OSA, -Parkinsons, stroke, TBI, Vitamin B12 insufficiency, Huntington disease, adrenal insufficiency, mononucleosis, systemic lupus erythematosus), adjustment disorder with depressed mood
* Patients diagnosed with concurrent ADHD, bipolar disorder, schizophrenia and schizoaffective disorder
Lieu de l'étude
University of Alberta
University of AlbertaEdmonton, Alberta
Canada
Contactez l'équipe d'étude
- Étude parrainée par
- University of Alberta
- Participants recherchés
- Plus d'informations
- ID de l'étude:
NCT04410575